CLINICAL TRIALS PROFILE FOR TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

All Clinical Trials for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	Canadian Institutes of Health Research (CIHR)	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	McGill University Health Center	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT00313807 ↗	Study of Intravenous Amino Acid Infusion to Prevent Contrast Dye Mediated Renal Damage	Withdrawn	Queen's University	Phase 2	2005-11-01	Exposure to radiographic contrast dye during coronary angiography is well known to cause either transient decreases in renal function or acute renal failure. Although the overall incidence is low, acute renal failure occurs most frequently in patients with both diabetes and chronic renal failure where the average reported incidence is upwards of 20%. The etiology of contrast-induced nephropathy is related to acute decline in renal blood flow following dye exposure resulting in ischemic injury at the level of the medulla. The development of acute renal failure following radiocontrast dye administration is significant because it contributes to morbidity and mortality in patients at risk. The administration of amino acids, either through intravenous infusion or a protein meal, results in a substantial increase in renal plasma flow (RPF) and glomerular filtration rate (GFR). In both healthy subjects and in those with chronic renal failure, an amino acid infusion produces a 20% rise in GFR and effective RPF. We hypothesize that the 20% rise in effective RPF and GFR following an amino acid infusion will counteract the radiocontrast dye-induced vasoconstriction and reduce the renal toxicity of contrast medium in a group of high-risk patients.

Clinical Trial Conditions for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

Condition Name

Condition Name for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Contrast Nephropathy	1
Renal Failure	1
Colorectal Cancer	1

Condition MeSH

Condition MeSH for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Renal Insufficiency	1
Kidney Diseases	1
Colorectal Neoplasms	1

Clinical Trial Locations for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

Trials by Country

+

−

Trials by Country for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
Location	Trials
Canada	1

Clinical Trial Progress for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Withdrawn	1
Active, not recruiting	1

Clinical Trial Sponsors for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
Queen's University	1
Canadian Institutes of Health Research (CIHR)	1
McGill University Health Center	1

Sponsor Type

Sponsor Type for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
Other	4

Clinical Trials Update, Market Analysis, and Projections for Travasol 2.75% in Dextrose 5% in Plastic Container

Introduction

Travasol, a formulation of amino acids, is widely used in total parenteral nutrition (TPN) to support patients who require intravenous nutrition. Here, we will delve into the current clinical trials, market analysis, and projections for Travasol 2.75% in Dextrose 5% in plastic containers.

Clinical Trials and Efficacy

Historical Context

Previous clinical trials have compared Travasol with other amino acid solutions. For instance, a comparative clinical trial between Travasol 8.5% without electrolytes and FreAmine II 8.5% showed that both products could promote positive nitrogen balance in patients with normal renal and hepatic function. However, there were no significant differences in renal function, liver function, or acid-base balance between the two groups[5].

Current Trials

There is a lack of recent, specific clinical trials focused solely on Travasol 2.75% in Dextrose 5% in plastic containers. However, the general efficacy of amino acid solutions in TPN is well-established. These solutions are crucial for providing essential nutrients to patients who cannot receive nutrition through the gastrointestinal tract.

Market Analysis

Demand and Usage

The demand for parenteral nutrition solutions, including Travasol, remains steady due to the ongoing need for intravenous nutrition in various clinical settings. Hospitals, intensive care units, and long-term care facilities are primary consumers of these products.

Market Competition

The market for parenteral nutrition solutions is competitive, with multiple manufacturers offering similar products. For example, there are 26 companies listed as suppliers for Travasol 2.75% Sulfite Free with Electrolytes in Dextrose 10% in plastic containers, indicating a diverse and competitive landscape[4].

Pricing and Cost

The cost of Travasol and similar products can vary based on the supplier, volume, and specific formulation. However, these costs are generally managed within the broader context of hospital budgets and healthcare reimbursement systems.

Market Projections

Growth Trends

The market for parenteral nutrition is expected to grow due to increasing healthcare needs, particularly in aging populations and those with chronic conditions requiring long-term nutritional support.

Technological Advancements

Advancements in packaging, such as the use of plastic containers, have improved the safety and convenience of parenteral nutrition solutions. These advancements are likely to continue, enhancing the market appeal of products like Travasol.

Regulatory Environment

Regulatory approvals and compliance are critical for the continued availability of these products. Manufacturers must adhere to strict guidelines set by regulatory bodies such as the FDA and EU health authorities to ensure product safety and efficacy.

Financial Projections

Revenue Forecast

While specific financial projections for Travasol 2.75% in Dextrose 5% are not available, the overall market for parenteral nutrition solutions is expected to see steady growth. This growth is driven by the increasing demand for nutritional support in various healthcare settings.

Market Share

The market share of Travasol and similar products will depend on factors such as pricing, product quality, and the strength of the distribution network. Companies with strong supply chains and competitive pricing are likely to maintain or increase their market share.

Key Players and Collaborations

Manufacturers and Suppliers

Several companies are involved in the manufacture and supply of Travasol and similar parenteral nutrition solutions. These companies often collaborate with healthcare providers and distributors to ensure widespread availability of their products.

Challenges and Opportunities

Supply Chain Disruptions

Supply chain disruptions can impact the availability of parenteral nutrition solutions. Manufacturers and suppliers must be prepared to mitigate these risks to ensure continuous supply.

Innovation and R&D

Continuous innovation in formulation, packaging, and delivery systems presents opportunities for growth. Companies investing in research and development are likely to stay ahead in the market.

Conclusion

Travasol 2.75% in Dextrose 5% in plastic containers remains a vital component of parenteral nutrition, supported by a well-established clinical efficacy profile. The market for these solutions is expected to grow, driven by increasing healthcare needs and technological advancements.

Key Takeaways

• Established Efficacy: Travasol and similar amino acid solutions have a proven track record in promoting positive nitrogen balance and supporting patients requiring intravenous nutrition.
• Market Growth: The market for parenteral nutrition solutions is expected to grow due to increasing demand in various healthcare settings.
• Competitive Landscape: The market is competitive, with multiple suppliers offering similar products.
• Regulatory Compliance: Adherence to regulatory guidelines is crucial for the continued availability of these products.
• Innovation: Continuous innovation in formulation, packaging, and delivery systems presents opportunities for market growth.

FAQs

What is Travasol used for?

Travasol is used in total parenteral nutrition (TPN) to provide essential amino acids to patients who cannot receive nutrition through the gastrointestinal tract.

Are there any recent clinical trials for Travasol 2.75% in Dextrose 5%?

There are no recent specific clinical trials focused solely on Travasol 2.75% in Dextrose 5% in plastic containers, but the general efficacy of amino acid solutions in TPN is well-established.

Who are the key players in the market for parenteral nutrition solutions?

Several companies are involved in the manufacture and supply of Travasol and similar parenteral nutrition solutions, including those listed as suppliers for Travasol 2.75% Sulfite Free with Electrolytes in Dextrose 10% in plastic containers[4].

What are the projected growth trends for the market?

The market for parenteral nutrition solutions is expected to grow due to increasing healthcare needs, particularly in aging populations and those with chronic conditions requiring long-term nutritional support.

How does the regulatory environment impact the market for Travasol?

Regulatory approvals and compliance are critical for the continued availability of these products. Manufacturers must adhere to strict guidelines set by regulatory bodies such as the FDA and EU health authorities to ensure product safety and efficacy.

Sources

1. Travere Therapeutics Provides Corporate Update and 2024 Outlook. Travere Therapeutics.
2. Quarterly Drug Pipeline: October 2024. Prime Therapeutics.
3. Tolebrutinib meets primary endpoint in HERCULES phase 3 study. Sanofi.
4. TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER-5. PharmaCompass.
5. Clinical Comparison of Two 8.5% Amino Acid Injection Products. PubMed.